Short answer
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
Cullinan Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Detailed results and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Cash and investments $313.8M at September 30, supporting operations into 2029 under the current plan
- Zipalertinib first-line NDA submission underway, with Cullinan eligible for $100M approval milestone and 50/50 U.S. profit share
- Zipalertinib monotherapy NDA remains under review, with FDA action date February 27, 2027
- Velinotamig SLE data showed complete renal response in 4 of 7 patients with elevated baseline proteinuria
- Third-quarter net loss $49.4M, or $0.74 per share, versus $50.6M, or $0.77, in 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cullinan Therapeutics, Inc. 8-K filings
Get the next CGEM 8-K as it lands
Follow CGEM for push alerts, or ask the research agent what this filing means.